Journal ArticleDOI
Novel agents and new therapeutics in castration-resistant prostate cancer.
Reads0
Chats0
TLDR
Recent advances in androgen targeting, chemotherapy, immunotherapy, and other targeted therapies have led to significant improvements in the care of CRPC patients.Abstract:
Purpose of reviewThis review highlights recent therapeutic advances in systemic therapies for prostate cancer (PCa).Recent findingsProgress in PCa therapeutics has been made during the past year with the approval of a vaccine therapy, second-line chemotherapy, and reported survival advantage for a Cread more
Citations
More filters
Journal ArticleDOI
Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
Bernard A. M. Fang,Žaklina Kovačević,Kyung Chan Park,Danuta S. Kalinowski,Patric J. Jansson,Darius J.R. Lane,Sumit Sahni,Des R. Richardson +7 more
TL;DR: The role of this important metastasis suppressor is described, the relationship between the molecular structure of this protein and its functions remains unclear and interesting unresolved issues regarding this protein are discussed.
Journal ArticleDOI
GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies
Patrizia Limonta,Marina Montagnani Marelli,Stefania Mai,Marcella Motta,Luciano Martini,Roberta M. Moretti +5 more
TL;DR: Tumor GnRH-R are now considered a very interesting candidate for novel molecular, GnRH analog-based, targeted strategies for the treatment of tumors expressing these receptors.
Book
Molecular Functions of the Iron-Regulated Metastasis Suppressor Ndrg1
TL;DR: In this article, the metastasis suppressor, NDRG1, was found to be pleiotropic and largely dependent on the genetic background of the cells examined, and the potential for NDRD1 to be utilized as a molecular target for the treatment of pancreatic cancer using a novel thiosemicarbazone compound.
Journal ArticleDOI
Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
TL;DR: This study provides a convenient method to predict multiple drug combination effects by the estimated CI values as well as cell viability data that can be used to design combination drug cocktails or delivery systems to improve chemotherapy for cancer patients.
Journal ArticleDOI
Progress of molecular targeted therapies for prostate cancers
TL;DR: Current developments in the field of targeted therapy, focusing specifically on treatments that can be applied to prostate cancers, are reviewed and aspects of the future direction of the field are described with respect to discovering biomarkers to aid in identifying responsive prostate cancer patients.
References
More filters
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Daniel P. Petrylak,Catherine M. Tangen,Maha Hussain,Primo N. Lara,Jeffrey A. Jones,Mary-Ellen Taplin,Patrick A. Burch,Donna L. Berry,Carol M. Moinpour,Manish Kohli,Mitchell C. Benson,Eric J. Small,Derek Raghavan,E. David Crawford +13 more
TL;DR: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
Journal ArticleDOI
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono,Stéphane Oudard,Mustafa Ozguroglu,Steinbjørn Hansen,Jean-Pascal Machiels,Ivo Kocák,Gwenaelle Gravis,Istvan Bodrogi,Mary J. MacKenzie,Liji Shen,Martin Roessner,Sunil Gupta,A. Oliver Sartor +12 more
TL;DR: Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Related Papers (5)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more